ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / XAIR
AMIX (34) CODX (29) WOK (51) ICCM (33) ⌘ Pro Terminal →

Beyond Air Inc. (XAIR) — RQD Stock Rating Cockpit

$2.21 -1.34% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.20

Beyond Air Inc. (XAIR) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $3.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on XAIR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is XAIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Beyond Air Inc. (NASDAQ: XAIR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.21 (-1.34% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XAIR ranks #815 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does XAIR compare to AMIX and CODX in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), XAIR carries a Roarable E (30/100 RQD), trailing P/E of 112.1x, gross margin of 3.3%, and ROIC of -35.0%. By comparison, AMIX (Autonomix Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and CODX (Co-Diagnostics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while XAIR leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for XAIR?
▼

Per XAIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001641631), Beyond Air Inc. generated $7.7M in revenue (+107.3% YoY), $34.3K in net income, and -$19.2M in free cash flow against $36.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.20 (-0.43%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (7)Whales (3)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.7% Base Target
$56 Bull$2 Base$2 Bear
📬 FREE XAIR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for XAIR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY XAIR SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 3.3% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
22
Grade E$2.19+0% Next Q
Q2 (-2Q)
25
Grade E$2.19+0.9% Next Q
Q3 (-1Q)
27
Grade E$2.21+0% Next Q
Current
30
Grade E$2.21-9.6% Hist 90D α
Trajectory: E (22) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a XAIR Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While XAIR currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.93) and Max Pain ($2.32) forces dealer call-delta covering toward $55.86.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $XAIR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “XAIR Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
40.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $2$2.21H: $53
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 17 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on XAIR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 3.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (22)

6/40 institutional & smart-money positioning score with 7/20 macro alignment.

Bull Case: Why Buyers Like XAIR
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Priced at 112x earnings—high expectations leave less room for a lukewarm quarter.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring XAIR)

  • ✓Walkthrough of XAIR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
XAIR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -80.85%▲ RESISTANCE BREAKOUT
2026-11-03O $2.31H $2.31L $2.21C $2.21VOL 12.5K
RES: $2.15SUP: $0.66SMA50: $2.93SMA200: $10.15
$33.84$25.22$16.61$7.99$-0.62RES $2.15SUP $0.66$2.212026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

XAIR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 XAIR Butterfly Map → + Track XAIR →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
48.0%/yr Implied 5Y Growth

vs. +107.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on XAIR today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for XAIR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for XAIR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (XAIR)

Health Care Rank #815 of 1015 ⚔️ AMIX vs XAIR Full Matrix →

1. Head-to-Head Health Care Peer Comparison (XAIR vs. AMIX, CODX, WOK, ICCM)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Beyond Air Inc. (XAIR) ranks #815 by composite RQD confidence (30/100, grade E) and #962 by equity capitalization ($3.7M). Within this direct 5-issuer industry benchmark cohort, XAIR leads on earnings valuation at 112.1x trailing P/E, while XAIR leads on capital efficiency and profitability with -35.0% ROIC and 3.3% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with XAIR at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
XAIR ACTIVE
Beyond Air Inc.
E 30/100 112.1x 3.3% -35.0% -1.34% $3.7M Benchmark Subject
AMIX
Autonomix Medical Inc.
E 34/100 — — -35.0% -7.18% $3.5M /amix-vs-xair →
CODX
Co-Diagnostics Inc.
E 29/100 — 64.3% -35.0% -3.65% $3.2M /codx-vs-xair →
WOK
WORK Medical Technology Group LTD (Class A)
D 51/100 — — — 0.00% $4.5M /wok-vs-xair →
ICCM
IceCure Medical Ltd.
E 33/100 — 36.3% -35.0% -3.14% $3.0M /iccm-vs-xair →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001641631 ↗

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Beyond Air Inc. (XAIR) reported GAAP revenue of $7.7M (+107.3% vs. FY2024 revenue of $3.7M , and +562.6% cumulative change since FY2023) , GAAP net income of $34.3K, operating cash flow of -$18.1M, and free cash flow of -$19.2M (+56.5% YoY). On the balance sheet, XAIR closed FY2025 with $36.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $7.7M $34.3K -$18.1M -$19.2M $36.8M —
FY2024 (FY) 2025-03-31 $3.7M $48.5K -$38.2M -$44.1M $34.1M —
FY2023 (FY) 2024-03-31 $1.2M $64.3K -$56.0M -$56.0M — —

3. XAIR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is XAIR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Beyond Air Inc. (NASDAQ: XAIR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $2.21 (-1.34% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, XAIR ranks #815 in composite RQD confidence.

How does XAIR compare to AMIX and CODX in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), XAIR carries a Roarable E (30/100 RQD), trailing P/E of 112.1x, gross margin of 3.3%, and ROIC of -35.0%. By comparison, AMIX (Autonomix Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $3.5M) and CODX (Co-Diagnostics Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $3.2M). Among the 5-stock peer group, XAIR leads on earnings multiple (112.1x) while XAIR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for XAIR?

Per XAIR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001641631), Beyond Air Inc. generated $7.7M in revenue (+107.3% YoY), $34.3K in net income, and -$19.2M in free cash flow against $36.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is XAIR trading relative to its 50-day, 200-day, and 52-week technical levels?

XAIR last traded at $2.21 (-1.34% on volume of 36,364 shares), positioning the stock -24.57% below its 50-day simple moving average ($2.93) and -78.23% below its 200-day simple moving average ($10.15). Across its 52-week range of $2.05 to $53.20, XAIR sits at the 0.3% percentile with a 14-day RSI of 40.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.93 to $2.49).

Direct Sub-Reports: XAIR RQD Cockpit XAIR 12M Forecast XAIR Earnings & Move XAIR Dividends & DRIP XAIR Insiders & 13F XAIR Whale Options XAIR Profit Sankey XAIR News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

XAIR — Beyond Air Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Beyond Air Inc. (XAIR) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $2.21 (-1.34% 1D, market capitalization $3.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 3.3%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (7/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Beyond Air Inc. (XAIR) is a NASDAQ-listed issuer in the Health Care sector, operating within the Medical/Dental Instruments industry,. Reported revenue across fiscal years 2023 through 2025 is present in the SEC financials, but the source does not describe how that revenue is generated.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Beyond Air Inc. (XAIR) reported $7.7M in annual revenue (up from $3.7M in FY2024, +107.3% YoY) and $34.3K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.2M revenue, $64.3K net income) through FY2025, XAIR scaled operating cash flow to -$18.1M and free cash flow to -$19.2M, backed by $36.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $2.05 – $53.20 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh 112.1x trailing P/E against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or second-order bottlenecks are identified in the source data. Sector and industry are recorded as Health Care and Medical/Dental Instruments only.

  • Key Question #1: Can XAIR sustain or expand its -60.0% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $7.7M and free cash flow of -$19.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is XAIR's 94.2x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

XAIR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Beyond Air Inc. (XAIR) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to XAIR Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

XAIR Bull vs. Bear Conversation Board — What's Your Call at $2.21?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON XAIR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on XAIR:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
DE DeltaGamma_99 RQD DEBATE OPENER • Options Flow Specialist 🐂 BULLISH 🎯 Target: $2.69 (+20.1%)
📌 Pinned Debate

Revenue grew from $1.2M in FY 2023 to $7.7M in FY 2025 and a Q3 2026 revenue growth of 27% was reported.

Long XAIR at $2.24 targeting $2.69. Revenue grew from $1.2M in FY 2023 to $7.7M in FY 2025 and a Q3 2026 revenue growth of 27% was reported.. Institutional whale score is 3/20 and the risk/reward vs. the $2.05 52-week low is skewed heavily in favor of bulls.

RetailWhale_TX 🐂 BULL

Both sides have a point here — XAIR's 10/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.

BE BearTrap_Alert RQD DEBATE OPENER • Cycle Peak Watcher 🐻 BEARISH 🎯 Target: $1.93 (-13.8%)
Spot @ $2.24

Operating income was negative in every reported period and free cash flow was -$19.2M in FY 2025 with ROIC at -35%.

Fading this rally in XAIR at $2.24. Operating income was negative in every reported period and free cash flow was -$19.2M in FY 2025 with ROIC at -35%.. With a beta of 1.0 and the stock sitting at $2.24 (52-wk range $2.05–$53.20), the easy multiple expansion is already priced in.

LIVE TAPE